Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Melamed

Showing results (131-140 of 311) with videos related to

Pageof 32
Sort By:
Acta Neurologica Scandinavica. Supplementum|January 1, 1977
Regional cerebral blood flow in the epileptic brain during the seizure-free intervalS Lavy, E Melamed, Z Portnoy, et al.
European Neurology|January 1, 1975
Central nervous system complication in a patient with chronic gaucher's diseaseE Melamed, C Cohen, D Soffer, et al.
Neurology|May 1, 1976
Interictal regional cerebral blood flow in patients with partial seizuresS Lavy, E Melamed, Z Portnoy, et al.
Perception & Psychophysics|February 1, 1978
The effect of prism strength and response mode on the magnitude of the correction effect in prism viewingL E Melamed, P A Beckett, B Wallace
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 1, 1987
The regional cerebral blood flow in patients under chronic hemodialytic treatmentD Gottlieb, B Mildworf, D Rubinger, et al.
Stroke|September 1, 1973
Hypertension and diabetes as risk factors in stroke patientsS Lavy, E Melamed, E Cahane, et al.
Advances in Neurology|January 1, 1987
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's diseaseE Melamed, M Globus, J Rosenthal, et al.
Clinical Neuropharmacology|April 18, 2001
The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's diseaseR Djaldetti, V Rosmarin, I Ziv, et al.
Neurology|March 1, 1996
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessmentR Djaldetti, I Ziv, A Achiron, et al.
Advances in Neurology|January 1, 1996
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's diseaseJ Zoldan, G Friedberg, A Weizman, et al.
Pageof 32

Showing results (131-140 of 311) with videos related to

Sort By:
Pageof 32
Acta Neurologica Scandinavica. Supplementum|January 1, 1977
Regional cerebral blood flow in the epileptic brain during the seizure-free intervalS Lavy, E Melamed, Z Portnoy, et al.
European Neurology|January 1, 1975
Central nervous system complication in a patient with chronic gaucher's diseaseE Melamed, C Cohen, D Soffer, et al.
Neurology|May 1, 1976
Interictal regional cerebral blood flow in patients with partial seizuresS Lavy, E Melamed, Z Portnoy, et al.
Perception & Psychophysics|February 1, 1978
The effect of prism strength and response mode on the magnitude of the correction effect in prism viewingL E Melamed, P A Beckett, B Wallace
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 1, 1987
The regional cerebral blood flow in patients under chronic hemodialytic treatmentD Gottlieb, B Mildworf, D Rubinger, et al.
Stroke|September 1, 1973
Hypertension and diabetes as risk factors in stroke patientsS Lavy, E Melamed, E Cahane, et al.
Advances in Neurology|January 1, 1987
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's diseaseE Melamed, M Globus, J Rosenthal, et al.
Clinical Neuropharmacology|April 18, 2001
The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's diseaseR Djaldetti, V Rosmarin, I Ziv, et al.
Neurology|March 1, 1996
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessmentR Djaldetti, I Ziv, A Achiron, et al.
Advances in Neurology|January 1, 1996
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's diseaseJ Zoldan, G Friedberg, A Weizman, et al.
Pageof 32